Nov 29, 2023 / 05:30PM GMT
Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division - MD & Fundamental Research Analyst
All right. Hi, everybody. Thanks so much for joining us this afternoon. I'm Elizabeth Anderson. I'm the healthcare technology and distribution analyst here at Evercore. Very pleased to be joined by ICON, Brendan Brennan, CFO as many of you know. Kate Haven, IR, as many of you probably also know as well.
Questions and Answers:
Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division - MD & Fundamental Research AnalystOkay. So maybe just to kick it off with sort of the question of the hour for the last many hours. Investors continue to be worried about a slowdown in pharma R&D spend. So how -- can you kind of give us a lay of the landscape right now? And how do you think about tracking it as we've gone through the last couple of months?
Brendan Brennan - ICON Public Limited Company - CFO
Yes, it's been an interesting period. We've obviously seen probably 2
Trustpilot
